All laboratory tests to be performed are listed in protocol Table 4. g Blood for anti -NY-ESO -1 T cell assessments to be collected only for subjects on prior to dosing on Day 1 and Day 92 only at select US sites. Additi onal blood samples for immunity assessments will be drawn for any subject who has no evidence of tumor progre ssion by RECIST v1.1 at 1 year at the same select US sites. h For circulating tumor genomics, please see lab manual. i For FCBP, serum and confirmation urine pregnancy testing will be performed by the local laboratory prior to dosing on Day 1; results mu st be negative. Serum pregnancy testing will be performed by the local laboratory prior to dosing on Day 92; results must be negative. Pregnancy te sting will be performed more frequently as required per local regulatory authority. j Vital sign measurement s will include body temperature, heart rate, respiratory rate, and resting systolic and diastolic blood pressure. On the day of each dosing, vital signs will be obtained no more than 60 minutes before dosing and 30 minutes after dosing (±10- minute window). k Once the Screening physical examination has been conducted, a simple symptom -directed physical examination should be performed for all subsequent visits. Measurements of body weight will be obtained at every visit. l Beginning in the Treatment period, ima ging will be performed at 8- week intervals after Day 1 administration of the first dose of the study drug for up to 1 year or until the time investigator -determined progressive disease, using RECIST v1.1, is documented. m QoL assessments will be conducted at the study site. In addition to the screening QoL assessment, the QoL assessment will be obtained on Day 1 prior to the first dose of study drug, at Day 92, and at 6 months and 12 months after Day 1. All subjects, regardless of their disease res ponse st atus, will continue to have QoL assessments performed for 12 months after Day 1. n All AEs and SAEs will be collected until 30 days after administration of the last dose of the study drug. Information on any SAEs and new malignancies that come to the atte ntion of the site staff that are considered at least possibly related to CMB305 will be collected until the time of last subj ect contact. o After Day 92, G305 or placebo will be given on Day 148 and at 8- week intervals as a boost for up to 1 year, or unti l unacceptable toxicity, or investigator - determined progressive disease, using RECIST v1.1, is documented, whichever occurs first. AEs will be reported at the subsequ ent visit and until at least 30 days after the last dose. p Peripheral blood will be coll ected at the following times after administration of the first dose of study drug on Day 1: no sooner than Day 92 (3 months) but up to 4 months; 6 months up to 9 months; and 1 year up to 15 months; and then yearly at no sooner than every 12 months but not more than 15 months up to the time of study closure. If all post- treatment assays are negative during the first year, then the yearly samples should be archived. Samples will be used for an assay to test for persistence of LV305. q The Day 92 biopsy may be obtained within ±2 weeks of Day 92, Day 365, and at time of progression event will be encouraged at the same selected US si tes per footnote “g”. r Survival status will be obtained by any means, which includes, but is not limited to, public records where allowed per local authority, telephone contact, during an in -clinic visit, chart review, or via communicating with an individual (e.g., family, friend, referring health care provider) wh o is knowledgeable of the subject’s survival status.